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High levels of X-linked Inhibitor-of-Apoptosis
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chemotherapy resistance in rectal cancer
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Abstract
Background: The mainstay of treatment in rectal cancer is neoadjuvant radio chemotherapy prior to surgery, in an
attempt to downstage the tumour, allowing for more complete removal during surgery. In 40 % of cases however,
this neoadjuvant radio chemotherapy fails to achieve tumour regression, partly due insufficient apoptosis signaling.
X-linked Inhibitor of Apoptosis Protein (XIAP) is an anti-apoptotic protein that has been reported to contribute to
disease progression and chemotherapy resistance.
Methods: We obtained rectal biopsy normal and matched tumour tissue from 29 rectal cancer patients with varying
degrees of tumour regression, and using Western blot, examined anti-apoptotic XIAP and pro-apoptotic Smac
protein levels in these tissues, with the aim to examine whether disturbed XIAP/Smac levels may be an indicator of
neoadjuvant radio chemotherapy resistance. Expression of inhibitor of apoptosis proteins cIAP-1 and cIAP-2 was also
examined.
Results: We found that levels of XIAP increased in accordance with the degree of radio chemotherapy resistance of
the tissue. Levels of this protein were also significantly higher in tumour tissue, compared to matched normal tissue
in highly resistant tissue. In contrast, Smac protein levels did not increase with radio chemotherapy resistance, and
the protein was similarly expressed in normal and tumour tissue, indicating a shift in the balance of these proteins.
Post treatment surgical resection tissue was available for 8 patients. When we compared matched tissue pre- and
post- radio chemotherapy we found that XIAP levels increased significantly during treatment in both normal and
tumour tissue, while Smac levels did not change. cIAP-1 and cIAP-2 levels were not differentially expressed in varying
degrees of radio chemotherapy resistance, and neoadjuvant therapy did not alter expression of these proteins.
Conclusion: These data indicate that disturbance of the XIAP/Smac balance may be a driver of radio chemotherapy
resistance, and hence high levels of XIAP may be a useful indicator of neoadjuvant radio chemotherapy resistance in
rectal cancer. Moreover, as XIAP levels increase with radio chemotherapy it is possible that a subset of more resistant
tumour cells survive this treatment and may be resistant to further adjuvant treatment. Patients with resistant
tumours highly expressing XIAP may benefit from alternative treatment strategies, such as Smac mimetics post
neoadjuvant radio chemotherapy.
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Background
Under homeostatic conditions a balance is struck be-
tween cell survival and cell death. Dysregulation of pro-
teins involved in apoptosis, or programmed cell death,
can upset this balance and push cells towards a disease
state. Excessive apoptosis can lead to neurodegenerative
diseases, and conversely situations where apoptosis is
deficient can result in carcinogenesis and chemo resist-
ance [1–4]. In the rectal cancer treatment setting neoad-
juvant radio chemotherapy is performed prior to surgery
in the hope of downsizing the tumour, allowing for more
complete removal during surgery [5]. Responses to neo-
adjuvant radio chemotherapy can vary greatly between
patients, and are categorised according to the Royal
College of Pathologists depending on extent of tumour
regression as RCPath A (complete tumour regression),
RCPath B (partial tumour regression), or RCPath C (no
marked tumour regression) [6]. In 15–27 % of patients
therapy is successful and a complete pathological re-
sponse is achieved, with patients displaying no residual
tumour [7–9]. On the other hand, in 30–40 % of pa-
tients no tumour regression is seen following neoadju-
vant radio chemotherapy [9, 10]. Molecular biomarkers
indicative of treatment response could help streamline
treatment selection and spare some patients from under-
going inefficient treatments.
Defective or deregulated apoptosis may be the driving
force behind this chemo resistance. X-linked Inhibitor of
Apoptosis Protein (XIAP) is an anti-apoptotic protein
that acts to suppress cell death via potent inhibition of
caspases [11–13]. High expression of this protein corre-
sponds to poor prognosis in many cancers [14–16], and
furthermore its expression level correlates positively with
disease progression [17]. As well as contributing to dis-
ease progression, XIAP was also reported to contribute
to chemotherapy resistance, and targeting this protein was
found to effectively sensitise cells to apoptosis and sup-
press tumour progression [18–21]. Second mitochondria-
derived activator of caspases (Smac) is a potent inhibi-
tor of XIAP. By binding to XIAP, Smac relieves caspase
inhibition and allows apoptosis to proceed. Cytosolic
Smac also binds to cIAP-1 and-2, inducing rapid autoubi-
quitination and proteasomal degradation of Smac and
cIAPs, resulting in an NF-κB-dependent secretion of
TNF-α and subsequent autocrine apoptosis induction
[22–24]. In cancer cells where XIAP is over expressed
Smac levels may be insufficient to block XIAP activity,
and this disturbed XIAP/Smac balance may contribute
to apoptotic resistance. Studies demonstrate that res-
toration of the XIAP/Smac balance in chemotherapy
resistant cancer cells can re-establish apoptosis [25, 26].
As a result synthetic Smac peptides are being investigated
for their therapeutic value in cancer. In conjunction with
other drugs, such as TRAIL, these compounds have been
successful in sensitising cancer cells to apoptosis and are
currently in clinical trials [27].
A better understanding of the molecular changes oc-
curring during neoadjuvant radio chemotherapy could
help identify markers of response, or tools to monitor
treatment response. Here we performed a quantitative
analysis of XIAP and Smac protein levels in the pretreat-
ment biopsy tissue of a cohort of rectal cancer patients
displaying variable responses to neoadjuvant radio che-
motherapy, with the aim of studying whether disturbed
XIAP/Smac levels are indicative of resistance to neoad-
juvant radio chemotherapy. Furthermore we examined
matched pre and post treatment tissue to detect changes
in XIAP or Smac expression induced by therapy. We
also examined cIAP-1 and cIAP-2 expression in this
tissue to examine whether these proteins may play a
contributory role when XIAP/Smac balance is disturbed.
Materials and methods
Patient cohort
Both biopsy and resection patient tissue was obtained
from the Departments of Surgery, and Pathology, Beau-
mont Hospital, Dublin, Ireland. At colonoscopy or rigid
sigmoidoscopy biopsy tumour and matched normal sam-
ples were collected. Biopsy tissue was collected in 21
male and 8 female patients (Table 1). The median age of
patients was 65, with ages ranging from 38 to 79. To
ensure consistent quality and tumour presence both
normal and tumour tissues were evaluated by an experi-
enced pathologist. Normal samples were obtained from
a distant site in the rectal tract that was macroscopically
unaffected and disease free. To be included in our
analysis tumour samples must have contained over 50 %
tumour cells and normal samples must have been free
of malignant cells. Following colonoscopy or rigid sig-
moidoscopy patients underwent radio chemotherapy.
The radio chemotherapy regimens consisted of radio-
therapy (50.4 GY in 28 fractions) and 5FU (5-Fluoro-
uracil), but some regimes varied slightly depending on
tolerance of the patient. Once patients completed their
course of treatment they underwent surgical resection.
Post-treatment surgical resection tissue was obtained
during surgery. Resection tissues were examined by a
pathologist and graded based on regression of the
tumour in response to therapy. Complete tumour re-
gression (RCPath A) was achieved in 5 patients; partial
tumour regression (RCPath B) in 10 patients, and no
marked tumour regression (RCPath C) was observed
in 14 patients. A dedicated clinical research nurse
reviewed medical records and gathered clinical infor-
mation. Patients with a family history of colorectal
cancer were excluded from analysis. Informed consent
was obtained from all patients and Beaumont Hospital
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Ethics Committee granted ethical approval for the
work.
Protein extraction and quantification
All tissue samples were lysed in 400 mL ice-cold buffer
containing 50 mmol/L HEPES (pH 7.5), 150 mmol/L
NaCl, 5 mmol/L Na-EDTA and protease inhibitor (Sigma).
Samples were maintained on ice and homogenised using
the Ultra-Turrax T25 Basic Homogeniser using 30 s
pulses to break down the tissue. Protein concentrations
were determined as follows, using the standard Pierce
Micro-BCA Protein Assay (Pierce, Northumberland, UK):
For calibration, a standard curve ranging from 0–12 μg
was set up using a bovine serum albumin standard.
Samples and standards were incubated at 37 °C for 30 min
and then absorbance was measured at 560 nm. The aver-
age absorbances were calculated for each sample and
standard. The slope of the BSA standard curve was used
to calculate the protein concentration of each sample.
Protein samples were prepared with SDS loading buffer
(100 nM TRIS-Cl pH 6.8, 4 % SDS, 0.2 % bromophenol
blue, 20 % glycerol) and denatured at 95 °C for 10 min.
An equal amount of 20 μg protein was loaded onto each
lane of 10–15 % SDS-polyacrylamide gels. Gels were run
at a voltage of 80 V until the proteins had migrated
through the stacking gel, and then at 120 V to drive the
proteins through the resolving gel. The running buffer
was composed of 25 mM Tris-Cl, pH 8.3, 250 mM glycine
and 0.1 % SDS. Once the proteins had migrated through
the gel the current was stopped and gels were transferred
to Nitrocellulose membranes. Gels were blotted to nitro-
cellulose membranes (Protean BA 83; 2 μm; Schleicher &
Schuell) in transfer buffer (25 mM Tris, 192 mM glycine,
20 % methanol (v/v), and 0.01 % SDS). Gels were trans-
ferred at 18 V for 60 min. The nitrocellulose membranes
were then blocked with 5 % nonfat dry milk in TBST
(15 mM Tris–HCl, pH 7.5, 200 mM NaCl, and 0.1 %
Tween 20) at room temperature for 1 h. Membranes were
then incubated with the primary antibodies overnight at
4 °C. The following primary antibodies were used: XIAP
(1:1000; Mouse monoclonal, 610762, BD transduction
laboratories, USA), Smac (1:1000; Rabbit polyclonal, AF-
789 R&D Systems, USA), cIAP1 (1:1000; Rabbit poly-
clonal, #4952, CST), cIAP2 (1:1000; Rabbit monoclonal,
#3130, CST) and b-actin (1:5000; Sigma). Secondary anti-
bodies were horseradish peroxidase (HRP)-conjugated
and were used at a dilution of 1:10,000 (Millipore), and
membranes were incubated for 1 h at room temperature.
Blots were developed using the enhanced chemilumines-
cence detection reagent (Millipore, Ireland). Chemilumin-
escence was detected at 12-bit dynamic range using a Fuji
LAS 4000 CCD system (Fujifilm UK Ltd., Bedfordshire,
UK). Densitometry was then performed. The intensity of
each band was calculated using Image J software. The
intensity of the loading control was deducted from the
intensity of the band of interest to eliminate any differ-
ences in protein levels owing to uneven loading, so that
each sample was normalized and could be compared.
Each sample was normalised to the intensity of its corre-
sponding β-Actin band.
Statistics
Statistical analyses were performed in Matlab (Math-
Works, Natick, MA, USA), and SPSS (IBM, Armonk,
NY, USA). Data are given as means ± s.e.m. For statis-
tical comparison Student’s t test or ANOVA and subse-
quent Tukey test were used for normal distributed data.
P values ≤ 0.05 were considered statistically significant.
Table 1 Table of patient clinical characteristics
ID Sex Age Neoadjuvant
therapy
RCPath Resection
tissue
Staging
T N M
1 M 73 50.4/28 + 5fu A x 3 2 0
2 F 42 54/30 + 5fu A x 2,3 1,2 0
3 F 38 50.4/28 + 5fu A x 3 1 x
4 M 75 54/31 + 5fu A x 3 2 x
5 M 51 50.4/28 + 5fu A x 3 2 0
6 M 66 50.4/28 + 5fu B √ 3 0,1 0
7 M 57 50.4/28 + 5fu B √ 3 1,2 0
8 F 72 50.4/28 + 5fu B x 3 2 0
9 M 65 50.4/28 + 5fu B x 3 x x
10 M 65 50.4/28 + 5fu B x 3 2 x
11 F 64 42.2/20 + 5fu B x 2 0 0
12 F 60 50.4/28 + 5fu B x 2 0 x
13 M 66 50.4/28 + 5fu B x 3 2 0
14 M 67 50.4/28 + 5fu B x 3 1 0
15 M 67 54/30 + 5fu B x 3 1 x
16 F 55 55.4/30 + 5fu C √ 3 2 0
17 F 75 45/25 + 5fu/RP C x 3 0 0
18 M 70 50.4/28 + 5fu C √ 3 2 0
19 M 79 50.4/28 + 5fu C x 3 2 0
20 M 76 43.2/25 + 5fu C √ 3 2 0
21 M 48 50.4/28 + 5fu C x 3 0 0
22 M 44 50.4/30 + 5fu C √ 3 2 0
23 M 47 50.4/28 + 5fu C √ 3 2 x
24 M 74 50.4/28 + 5fu C √ 3 2 x
25 M 45 50.4/28 + 5fu C x 3 2 x
26 M 62 50.4/30 + 5fu C x 3 1 x
27 M 64 50.4/28 + 5fu C x 3 1 x
28 F 41 50.4/28 + 5fu C x 3 1 x
29 M 71 50.4/28 + 5fu C x 3 2 x
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Results
XIAP level increases in accordance with tissue resistance
to radio chemotherapy in tumour tissue, but not normal
tissue
Pre-treatment biopsy tumour and matched normal tissue
samples were obtained at colonoscopy or rigid sigmoid-
oscopy (Fig. 1) from 29 rectal cancer patients. Using
quantitative Western blotting, the expression levels of
XIAP and Smac in tumour and matched normal biopsy
tissue were determined in all 29 patients. Representative
Western blot images for 6 patients (3 RCPath A, 2
RCPath B and 1 RCPath C) are shown in Fig. 2a. Beta
Actin was used as a loading control. HeLa cells were used
as a standard as previously described [28] (Fig. 2a).
Clinical data was then examined and protein levels were
correlated to RCPath grade (Table 1).
When we examined expression levels in all 29 patients
we see that as tumour tissue became more radio chemo-
therapy resistant, from RCPath A to RCPath C, XIAP
levels significantly increased (p = 0.025) (Fig. 2b). Con-
versely Smac levels did not increase with RCPath grade
(Fig. 2c). This indicated a shift in the expression of these
two proteins as tissue becomes more resistant to the-
rapy. While this pattern was very evident in tumour
tissue, matched normal tissue did not follow this trend.
In normal tissue both XIAP and Smac levels remained
unchanged throughout the varying grades of radio che-
motherapy resistance. In RCPath C patients XIAP pro-
tein levels were significantly raised in the tumour tissue
compared to the matched normal tissue (p = 0.007).
These data demonstrated the importance of the XIAP/
Smac balance and as XIAP levels increase and outweigh
Smac levels, cells may be able to avoid apoptosis, via
increased caspase inhibition, and thus become more re-
sistant to therapy. Due to limited availability of biopsy
tissue cIAP-1 and-2 were examined in only 14 biopsy
tissues. Of these tissues 2 were RCPath A, 4 were RCPath
B and 8 were RCPath C. Consequently RCPath A and B
were pooled and compared to RCPath C. Both cIAP-1
and-2 protein levels were similar in all patients regardless
of pathological response to neoadjuvant radio chemo-
therapy, suggesting that these proteins do not play a
contributory role when the XIAP/Smac balance is
disturbed (Fig. 2d, e). When we investigated whether
XIAP level in biopsy tissue may have predictive power in
selecting patients who respond to therapy, we found that
XIAP levels could predict patients that responded to
therapy with a sensitivity of 80 % and a specificity of
88 %, outperforming TNM staging which could not pre-
dict patient response to therapy, with a sensitivity 20 %
and a specificity 100 %.
XIAP expression increases in tumour tissue during radio
chemotherapy
Following neoadjuvant radio chemotherapy patients un-
derwent surgery to remove any remaining tumour. In
RCPath A patients, where a complete pathological re-
sponse was achieved, no surgical resection tissue was
available. In 8 RCPath B and C patients, where neoadju-
vant radio chemotherapy induced only partial tumour
regression, or no tumour regression respectively, surgical
resection tissue was available post treatment (Fig. 1).
Using Western blotting we examined XIAP, Smac
and cIAP-1 and-2 levels in these samples. XIAP levels
were compared in pretreatment biopsy tissue and post
treatment resection tissue. In tumour (Fig. 3a) XIAP
expression increased significantly during the course of
neoadjuvant radio chemotherapy (p = 0.004662). XIAP
expression in matched normal tissue also increased
but not significantly (p = 0.082984). Smac levels were also
compared in pretreatment biopsy tissue and post treat-
ment resection tissue (Fig. 4a, b). We saw no significant
change in Smac expression in normal or tumour tissue
pre and post treatment. This suggested that cancer cells
that survive treatment responded by increasing their
XIAP protein levels which may have resulted in radio
chemotherapy resistance. Due to limited availability of
Fig. 1 Sample collection and clinical response. Biopsy samples
were obtained at colonoscopy or rigid sigmoidoscopy. Patients
then underwent neoadjuvant radio chemotherapy. Patient responses
are categorised depending on the degree of tumour regression
following neoadjuvant radio chemotherapy as RCPath A (complete
tumour regression), RCPath B (partial tumour regression), or RCPath
C (no marked tumour regression). Following neoadjuvant radio
chemotherapy, resection tissue was obtained from surgery where
available
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tissue cIAP-1 and-2 was examined in tumour tissue only
(Fig. 5a, b; cIAP-1 n = 6; cIAP-2 n = 5). Neither protein
was affected by neoadjuvant radio chemotherapy, with no
changes seen in expression levels in tumour tissue pre
and post treatment.
Discussion
In rectal cancer patients routinely undergo neoadjuvant
radio chemotherapy. Radio chemotherapy, and also radio-
therapy alone, prior to surgery has been shown to reduce
rates of local recurrence and improve disease free survival,
Fig. 2 Elevated XIAP protein levels prior to neoadjuvant radio chemotherapy indicate resistance to therapy in rectal cancer patients. Biopsy tissue
samples of 29 rectal cancer patients were obtained at colonoscopy or rigid sigmoidoscopy. a Representative Western blot images for 6 patients
(3 RCPath A, 2 RCPath B and 1 RCPath C) are shown in Fig. 2a. The expression levels of XIAP and Smac in tumour (T) and matched normal tissue
(N) were determined by quantitative Western blotting. Beta Actin was used as a loading control. HeLa cells were used as a standard. b Protein
expression levels for all 29 patients were then correlated with tumour regression grade. Levels of XIAP protein increased in accordance with radio
chemotherapy resistance (p = 0.025) in tumour tissue. XIAP protein levels are also significantly raised in the tumour tissue compared to the matched
normal tissue in RCPath C patients (p = 0.007). c Smac protein was not differentially expressed in RCPath grades. Furthermore there was no significant
difference in Smac expression in tumour and matched normal tissue. (d, e) Expression levels of cIAP-1 (d) and cIAP-2 (e) were also determined by
quantitative Western blotting in 14 biopsy tissues and then correlated with tumour regression grade. Neither protein was differentially expressed in
RCPath grades nor was there a significant difference in expression in tumour and matched normal tissue
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when compared to surgery alone [29, 30]. Patients who
experience complete pathological response to neo-adju-
vant radio chemotherapy experience low incidence of local
recurrence and distant metastases [7, 8]. A response to
neo-adjuvant radio chemotherapy of 95 % or greater is
associated with a good long term outcome for the patient
[31]. Many patients respond poorly to neoadjuvant radio
chemotherapy but the reason for this is currently not well
understood [9, 10, 32]. We examined XIAP, cIAP-1, cIAP-
2 and Smac protein levels in a cohort of rectal cancer
patients to examine whether more chemo resistant tis-
sue displayed an altered protein expression. We found
that XIAP levels in tumour tissue increased as chemo
resistance grades progressed from RCPath A, through
RCPath B, to RCPath C, suggesting XIAP may play a
critical role in resistance to neoadjuvant radio chemo-
therapy. Furthermore our study highlights the potential
of XIAP as a marker of response to neoadjuvant radio
chemotherapy.
XIAP expression has previously been shown to be an
important factor in cancer progression. In colorectal
cancer cells high XIAP mRNA levels have been shown
to be indicative of tumour differentiation, invasion and
progression [33]. As well as contributing to disease
progression XIAP was also reported to contribute to
chemotherapy resistance [34]. In a cohort of 90 ovarian
Fig. 3 XIAP expression increases in tumour tissue during radio chemotherapy. For 8 patients where pre-treatment biopsy and matched post-
treatment surgical resection tissue was available the expression levels of XIAP in tumour and matched normal tissue were once again determined
by quantitative Western blotting. a In individual patients, all but one patient had increased XIAP levels in resection tumour tissue, compared to
matched tumour biopsy tissue, and XIAP expression was significantly increased in post treatment resection tumour tissue, when compared to
pre-treatment biopsy tumour tissue (p = 0.004662). b In matched normal tissue 6 out of 8 patients had increased XIAP levels in resection tumour
tissue, compared to matched tumour biopsy tissue. This trend was not significant
Fig. 4 Smac expression does not change in normal and tumour tissue during radio chemotherapy. Smac expression levels in tumour and matched
normal tissue were once again determined by quantitative Western blotting in pre-treatment biopsy and matched post-treatment surgical resection
tissue, which was available for 8 patients. Smac expression was not significantly increased in post treatment resection (a) tumour and (b) normal
tissue, when compared to pre-treatment biopsy tumour and normal tissue
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clear cell carcinoma patients high XIAP expression was
found to correlate with lower chemotherapy response
rates and also a worse progression free and overall sur-
vival for patients [19]. High levels of XIAP in lung cancer
cells resulted in cisplatin mediated apoptosis resistance,
and this apoptosis could be restored once XIAP was
silenced [20]. Similar trends were reported in colorectal
and breast cancer cell lines, where ceramide was found
to effectively sensitise cells to apoptosis and also suppress
tumour progression, via targeting of XIAP [18]. These
studies highlight the importance of XIAP in cancer
progression and demonstrate a crucial role for XIAP in
triggering resistance to chemotherapeutic drugs.
Our work demonstrated that while XIAP expression
increased as chemo resistance grades progressed from
RCPath A, through RCPath B, to RCPath C, Smac levels
remained constant. Smac is XIAP’s main antagonist,
blocking XIAP’s caspase inhibitory function and allowing
apoptosis to proceed. cIAP-1 and cIAP-2 are other
inhibitor of apoptosis proteins that Smac binds to. As
the XIAP/Smac balance shifts we saw no differential
regulation of these proteins indicating that they play no
contributory role when XIAP/Smac balance is disturbed.
In many cancer cells as XIAP levels increase Smac levels
do not mirror this pushing the cells into a more anti-
apoptotic state. Findings similar to ours were previously
reported in renal cell carcinomas (RCC). Yan et al. inves-
tigated XIAP and Smac expression in RCC, and found
that Smac levels remained constant regardless of tumor
progression, despite XIAP expression increasing signifi-
cantly from early to advanced tumor stages. This dis-
turbed XIAP/Smac balance may contribute to apoptotic
resistance in RCC [25]. Another scenario where disrup-
tion of this protein balance was found to contribute to
disease progression is Hodgkins disease. Hodgkins and
Reed Sternberg cells and Hodgkin lymphoma derived B
cells involved in this disease express high levels of XIAP.
When the XIAP/Smac balance was restored in these
cells they become re-sensitised to apoptosis [26].
As XIAP levels rise and the XIAP/Smac balance shifts
Smac levels may not be sufficient to overcome XIAP’s
anti-apoptotic action. Restoration of this balance may
push cells back towards apoptosis and hence synthetic
Smac peptides and small molecule Smac mimetics are
being examined as novel cancer therapeutics. In combin-
ation with chemotherapy and radiotherapy these com-
pounds have been reported to sensitise resistant cancer
cells to apoptosis via modulation of both the apoptotic
and NF-κB pathways [35–37]. The importance of the
Smac/XIAP ratio in treatment responses to Smac mi-
metics was highlighted in childhood acute lymphoblastic
leukaemia where XIAP is upregulated. Antagonism of
XIAP, via a Smac mimetic, led to a significant increase
in apoptosis in this setting [16]. Combined Smac mi-
metics and TRAIL treatment also reduced metastatic
behaviour and cell migration [38]. Recent reports have
highlighted that Smac mimetics can also trigger necrop-
tosis as an alternative form of cell death to overcome
apoptosis resistance in acute myeloid leukaemia cells
[39]. Our data suggests that in the rectal cancer setting
those patients who were unresponsive to traditional
therapies and displayed high XIAP levels may benefit
from Smac mimetic treatment to re-establish the XIAP/
Smac balance, and in turn re-sensitise cells to therapy.
Fig. 5 cIAP-1 and −2 expression does not change in normal and tumour tissue during radio chemotherapy cIAP-1 and −2 expression levels in
tumour tissue were determined by quantitative Western blotting in pre-treatment biopsy and matched post-treatment surgical resection tissue.
cIAP-1 was examined in 6 patients and cIAP-2 was examined in 5 patients. Expression of (a) cIAP-1 and (b) cIAP-2 was not significantly increased
in post treatment resection tumour tissue, when compared to pre-treatment biopsy tumour and normal tissue
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As well as increasing expression in radio chemother-
apy resistant cells, we found that XIAP expression was
also up regulated by neoadjuvant radio chemotherapy.
Levels of XIAP in both normal and tumour tissue were
significantly increased in post treatment surgical resec-
tion tissue, when compared to pretreatment biopsy tis-
sue. Smac levels did not increase in response to therapy
in either normal or tumour tissue, which once again
contributes to a disruption of XIAP/Smac expression in
cells. Recently it has been reported that chemotherapy
induced enhanced XIAP expression, partially mediated
through PI3K/Akt signalling, resulting in chemo resist-
ance in breast cancer cells [40]. These data suggest that
following treatment sensitive cells are killed off but a
cohort of more resistant cells with high levels of XIAP
remain. This has significant implications for further ad-
juvant treatment, as this more resistant population may
continue to proliferate and be refractory to traditional
therapies, highlighting another scenario where Smac
mimetics would be an attractive alternative treatment
regime.
Conclusions
Our work highlights XIAP’s central role in resistance to
neoadjuvant radio chemotherapy, leading to reduced ther-
apy success. The use of Smac mimetics in this setting
may restore the XIAP/Smac balance, in turn restoring
apoptosis and leading to improved patient outcomes. Fur-
thermore XIAP levels increase in response to neoadjuvant
radio chemotherapy. Up regulation of this protein may
lead to a more resistant phenotype in the adjuvant treat-
ment setting, and patients defined by this XIAP over
expression may benefit from alternative adjuvant treat-
ment regimes, such as Smac mimetics.
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